Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Henney highlights priorities for cash-strapped FDA as she embraces the letter and spirit of the law

This article was originally published in Clinica

Executive Summary

The FDA's new commissioner, Jane Henney, said in her first major public speech in the US last week that she would focus on five top priorities: blood safety; tobacco regulation; food safety; implementation of the FDA Modernization Act of 1997(FDAMA); and promoting the agency's scientific base. In her brief remarks at the Food and Drug Law Institute's annual meeting she made no mention of the medical device industry.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT082869

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel